US medical oncologists may lack understanding of biosimilars and have limited access to education about these products, a survey suggests.
Using telehealth saved cancer patients an estimated $147.40 to $186.10 per visit, as well as 1.2 hours of in-clinic time and 2.9 hours of roundtrip driving time.
Combination ponatinib and blinatumomab produced durable responses in patients with newly diagnosed Ph+ acute lymphoblastic leukemia in a phase 2 trial.
Talquetamab produced responses in more than 70% of patients with relapsed/refractory multiple myeloma who received the recommended phase 2 doses.
The combination of ibrutinib and tisagenlecleucel produced durable responses in patients with relapsed/refractory mantle cell lymphoma.
Pivekimab sunirine plus azacitidine and venetoclax has demonstrated activity in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia.
The prior authorization process can delay cancer care, leading to disease progression and death, according to a survey of ASCO members.
The COVID-19 pandemic has hindered the early diagnosis and treatment of cancer, and this may have set back cancer outcomes by almost a decade in Europe, a new report suggests.
In the absence of immunosuppression, systemic cancer therapies do not increase the risk of severe COVID-19 or cytokine storm, a study suggests.
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
